Breaking News
EnGeneIC publishes the COVID-EDV vaccine’s novel mechanism of action in a leading Immunology journal
The completely unique mechanism of action of the world’s first COVID-19 vaccine to stimulate “high affinity” antibodies which neutralise most COVID variants has been published by EnGeneIC in the prestigious journal, Frontiers in Immunology (27th January, 2023).
Works against mutant strains including Delta & Omicron. No need for refrigeration during transport and storage. No added stabilisers or chemicals. Safety and immune response clinical trial recruiting now in Melbourne, Sydney & Perth to follow. Efficacy trial planned for USA.
For more information about becoming a volunteer for the COVID-19 EDV™ Vaccine Trial contact our Clinical Trials Team.